Press Releases

Celleron Therapeutics announces Initiation of Patient Enrolment into the Expansion Cohort of its CXD101 Phase 1 Clinical Trial

Jun 11, 2018

The expansion cohort of our Phase I clinical trial is open to patient enrolment.

Read More

Celleron Therapeutics Selects Syneos Health to Conduct Clinical Trial Programme for CXD101 on MAY 1, 2018

May 1, 2018

The company has selected Syneos Health, a leading biopharmaceutical solutions organization, to conduct clinical trials for its lead compound CXD101 in colorectal cancer.

Read More

Celleron Therapeutics announces MHRA Clinical Trial Authorisation for CXD102 in Microsatellite-Stable Colorectal Cancer

Mar 26, 2018

UK MHRA has granted approval for the conduct of a clinical trial with its lead compound CXD101 in colorectal cancer.

Read More

Celleron Therapeutics appoints Bill Fleming as its Chief Financial Officer

Feb 9, 2018

Oxford 7 February 2018; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced

Read More

Celleron Therapeutics announces EMA COMP Orphan Drug designation for CXD101 in peripheral T-cell lymphoma

Dec 6, 2017

Oxford, UK, 6 December 2017 – Celleron Therapeutics, the UK-based company developing personalised medicine for cancer patients, has today announced

Read More

Celleron Therapeutics announces Licensing and Co-Development Agreement with Nuance Biotech for China and South Africa

Nov 13, 2017

Oxford 13 November 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced

Read More

Dr Chris Towler joins the Board of Celleron Therapeutics

Jul 24, 2017

Oxford 24th July 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced

Read More

CXD101 presented at 3rd Shanghai International Forum

Jul 3, 2017

Oxford 2 July 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced

Read More

Dr. Doug Manion joins Board of Celleron Therapeutics

Jun 1, 2017

Oxford 24th May 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced

Read More

CXD101 update presented at Inaugural Meeting of Oxford Centre for Cancer Gene Research

Apr 18, 2017

Oxford 12 April 2017; Celleron Therapeutics Limited, the UK based precision cancer medicines company, developing novel small molecule therapeutics, announced

Read More
Do NOT follow this link or you will be banned from the site!